Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increased product competition, generic and/or branded- generic price erosion, and cost consciousness will constrain growth in the asthma drug market as sales will decline from $10.9 billion in 2007 to $10.1 billion in 2017 in the world's major pharmaceutical markets.

The new Pharmacor report entitled Asthma finds that although sales will decline over the next decade in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, the launch of several new long-acting beta- agonist/inhaled corticosteroid (LABA/ICS) combinations will drive growth in this class. However, none of five new LABA/ICS therapies that are set to launch by 2017 will overtake the current market leader in this class- GlaxoSmithKline's Advair/Seretide/Adoair, owing to its well-established patient share.

The report also finds that although the asthma market is saturated with many safe and effective drugs, pharmaceutical companies continue to develop new therapies to maximize their earning potential in this lucrative market.

"Asthma therapies that are emerging over the next ten years in the U.S., European, and/or Japanese markets that offer improved convenience will capture market share but will still not surpass sales of Advair/Seretide/Adoair," said Amy Whiting, Ph.D. analyst at Decision Resources. "Other key players will rely on competitive pricing, incremental gains in safety, or improved efficacy to differentiate themselves from competitors."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction

View Now